Skip to content

MERRIMACK PHARMACEUTICALS INC

CIK 0001274792

← back to feed
Revenue (TTM)
$99.47M
+61.6% YoY Q1 May 2024
Net Income (TTM)
−$2.63M
+82.5% YoY Q1 May 2024
EPS Diluted (TTM)
$13.86
+27.3% YoY Q1 May 2024
Gross Margin
96.7%
Q1 May 2024
Operating Margin
-2.2%
Q1 May 2024
Net Margin
-2.6%
Q1 May 2024
Free Cash Flow (TTM)
−$5.2M
Q1 May 2024
Cash
$234.16M
Q1 May 2024
Total Debt
$50.94M
Q1 May 2024
Shares Outstanding
14.79M sh
Q1 May 2024

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings